Nomura Holdings
IMNP

Nomura Holdings’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Nomura Holdings’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,160
Closed -$27K – 2214
2015
Q3 		$27K Buy
+1,160
New +$36.5K ﹤0.01% 1575

Other funds holding IMNP

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
EEG
E.E. Geduld $178M AUM 29.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IFS
Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

Nomura Holdings's IMNP Position: Q4 2015 in Review

Nomura Holdings sold out of Immune Pharmaceuticals Inc. (IMNP) in Q4 2015, closing a stake of 1,160 shares — an estimated $27K sold.

Nomura Holdings first reported a position in IMNP in Q3 2015 and held it in 1 quarter. The position peaked at $27K in Q3 2015. 15 funds tracked by Wall St. Rank hold IMNP as of Q4 2015.

  • Nomura Holdings reported no remaining Immune Pharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
  • Nomura Holdings sold 1,160 Immune Pharmaceuticals Inc. shares in Q4 2015, an estimated $27K.
  • Nomura Holdings first reported a position in Immune Pharmaceuticals Inc. in Q3 2015 and held it in 1 quarter.
  • Nomura Holdings's Immune Pharmaceuticals Inc. position peaked at $27K in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q4 2015.

Based on Nomura Holdings's 13F filing for Q4 2015, filed 12 Feb 2016.